More recent data have built upon these studies to show that high levels of Hras are required to activate tumor suppressor pathways in vivo18, and that doubling the levels of oncogenic Kras is sufficient to cause metabolic rewiring leading to differences in therapeutic susceptibilities19. The gene discussed is KRAS; the disease is neoplasm.